Literature DB >> 2697186

Uptake, metabolism and antiproliferative effect of estramustine phosphate in human glioma cell lines.

E von Schoultz1, P O Gunnarsson, R Henriksson.   

Abstract

The uptake, metabolism and antiproliferative effects of estramustine phosphate, a cytotoxic agent used in prostatic cancer, were investigated in the two human malignant glioma cell lines U-105 MG and U-251 MG. The primary metabolite estramustine had a dose-dependent inhibitory effect on cell proliferation within the concentration range 5-20 micrograms/ml. After incubation with 3H-estramustine phosphate in both cell lines, a progressive uptake of radioactivity was recorded during 24 hours. A significant metabolism of parent estramustine phosphate into estramustine and estramustine, which is a well known part of the metabolic pathway in man, was also demonstrated. In conclusion, certain cultured malignant glioma cells display significant uptake, retention and metabolism of estramustine phosphate and further studies are indicated to assess the clinical implications of these findings.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2697186

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 2.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

3.  High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.

Authors:  Roger Henriksson; Annika Malmström; Per Bergström; Gertrud Bergh; Thomas Trojanowski; Lars Andreasson; Erik Blomquist; Sonny Jonsborg; Tomas Edekling; Pär Salander; Thomas Brännström; A Tommy Bergenheim
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

4.  Targeting microtubule-associated proteins in glioblastoma: a new strategy for selective therapy.

Authors:  J M Piepmeier; P E Pedersen; D Yoshida; C Greer
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

5.  Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion.

Authors:  P Behnam-Motlagh; O Jonsson; K G Engström; R Henriksson; K Grankvist
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Authors:  Howard Landy; Arnold Markoe; Priscilla Potter; Garrett Lasalle; Angela Marini; Niramol Savaraj; Isildinha Reis; Deborah Heros; Medhi Wangpaichitr; Lynn Feun
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells.

Authors:  A T Bergenheim; M Hartman; J Bergh; P A Ridderheim; R Henriksson
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo.

Authors:  A T Bergenheim; B Zackrisson; J Elfverson; G Roos; R Henriksson
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study.

Authors:  D Yoshida; J M Piepmeier; T Bergenheim; R Henriksson; A Teramoto
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.

Authors:  A T Bergenheim; P O Gunnarsson; K Edman; E von Schoultz; M I Hariz; R Henriksson
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.